Outcome of azacitidine therapy in acute myeloid leukaemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

Research output: Contribution to journalArticlepeer-review

Authors

  • Lynn Quek
  • Emmanouela Gbandi
  • Corran Roberts
  • Marlen Metzner
  • Natalia Garcia-Martin
  • Alison Kennedy
  • Angela Hamblin
  • Sandeep Nagra
  • Louise Hopkins
  • Mary Frances McMullin
  • Srinivas Pillai
  • Richard Kelly
  • Shamyla Siddique
  • Michael Dennis
  • Jamie D. Cavenagh
  • Paresh Vyas

Abstract

Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML) but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined. Co-administration of histone deacetylase inhibitors, such as vorinostat (VOR), is reported to improve the clinical activity of AZA but this has not been prospectively studied in AML. Experimental Design: We compared outcomes in 259 adults with AML (n=217) and MDS (n=42) randomized to receive either AZA monotherapy (75 mg/m2 × seven days every 28 days) or AZA combined with VOR 300 mg bd on days 3-9 po. Next generation sequencing was performed in 250 patients on 41 genes commonly mutated in AML. Serial immunophenotyping of progenitor cells was performed in 47 patients. Results: Co-administration of VOR did not increase the overall response rate (P=0.84) or overall survival (OS) (P=0.32). Specifically, no benefit was identified in either de novo or relapsed AML. Mutations in the genes CDKN2A (P=0.0001), IDH1 (P=0.004) and TP53 (P=0.003) was associated with reduced OS. Lymphoid multi-potential progenitor populations were greatly expanded at diagnosis and although reduced in size in responding patients remained detectable throughout treatment. Conclusion: This study demonstrates no benefit of concurrent administration of VOR with AZA but identifies a mutational signature predictive of outcome after AZA based therapy. The correlation between heterozygous loss of function CDKN2A mutations and decreased OS implicates induction of cell cycle arrest as a mechanism by which AZA exerts its clinical activity.

Details

Original languageEnglish
Pages (from-to)6430-6440
JournalClinical Cancer Research
Volume23
Issue number21
Early online date1 Aug 2017
Publication statusPublished - Nov 2017

Keywords

  • CDKs and CDK inhibitors, Acute Myeloid Leukemia, molecular prognosis, DNA methylation, cell cycle checkpoint